New approach in the interpretation of the adipose tissue;Szemléletváltás a zsírszövet megítélésében

Orvosi Hetilap

Volumn 151, Issue 31, 2010, Pages 1252-1260

  Antal, Magda ^a   Regöly Mérei, Andrea ^a  

^a NONE

Author keywords

adiponectin; leptin; omentin; resistin; visceral and subcutaneous adipose tissue; visfatin

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; HORMONE; LEPTIN; LEPTIN RECEPTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN; PEPTIDE HORMONE; RESISTIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ENDOCRINE GLAND; HUMAN; MEDICAL LITERATURE; METABOLISM; REVIEW;

ADIPOKINES; ADIPONECTIN; ADIPOSE TISSUE; CYTOKINES; HUMANS; LECTINS; LEPTIN; LIVER; MUSCLE, SKELETAL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PANCREAS; RECEPTORS, ADIPOKINE; RECEPTORS, ADIPONECTIN; RECEPTORS, LEPTIN; RESISTIN;

EID: 77955018004     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28901     Document Type: Review

References (49)

1. Fischer-Posovszky, P., Wabitsch, M., Hochberg, Z.: Endocrinology of adipose tissue-an update. Horm. Metab. Res., 2007, 39, 314-321.
2. Frühbeck, G.: Overview of adipose tissue and its role in obesity and metabolic disorders. Methods in Molecular Biology, 2008, 456, 1-22.
3. Winkler G., Cseh K.: Molekularis tenyezõk szerepe az inzulinrezisztencia - elhizas - 2-es tipusu diabetes patogenetikai kapcsolatban. Orv. Hetil., 2009, 150, 771-780.
4. Császár A.: A zsirszovet endokrin funkcioja es kapcsolata a kardiovaszkularis kockazat kialakulasaval. Cardiol. Hung., 2003, 33, 245-250.
5. Yang, R-Z., Lee, M-J., Hu, H. és mtsai: Identifi cation of omentin as a novel depot-specifi c adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab., 2006, 290, E1253-E1261.
6. Klöting, N., Berthold, S., Kovacs, P. és mtsai: MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS ONE, 2009, 4, e4699.
7. Ingalls, A. M., Dickie, M. M., Snell, G. D.: Obese, new mutation in house mouse. J. Hered., 1950, 41, 317-318.
8. Coleman, D. L.: Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetol., 1978, 14, 141-148.
9. Friedman, J. M., Leibel, R. L., Siegel, D-S. és mtsai: Molecular mapping of the mouse ob mutation. Genomics, 1991, 11, 1054-1062.
10. Zhang, Y., Proenca, R., Maffei, M. és mtsai: Positional cloning of the mouse obese gene and its human homologue. Nature, 1994, 372, 425-432.
11. Frühbeck, G.: Intracellular signalling pathways activated by leptin. Biochem. J., 2006, 393, 7-20.
12. Hegyi, K., Fülöp, K., Kovács, K. és mtsai: Leptin-induced signal transduction pathways. Cell. Biol. Internat., 2004, 28, 159-169.
13. Tartaglia, L. A., Dembski, M., Weng, X. és mtsai: Identifi cation and expression cloning of a leptin receptor, OB-R. Cell, 1995, 83, 1263-1271.
14. Knudson, J. D., Dick, G-M., Tune, J. D.: Adipokines and coronary vasomotor dysfunction. Exp. Biol. Med., 2007, 232, 727-736.
15. Sinha, M. K., Opentanova, I., Ohannesian, J. P. és mtsai: Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J. Clin. Invest., 1996, 98, 1277-1282.
16. Isidori, A. M., Strollo, F., More, M. és mtsai: Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J. Clin. Endocrinol. Metab., 2000, 85, 1954-1962.
17. Antal M., Regöly-Mérei A., Nagy K. és mtsai: Van-e kituntetett merõmodszer az elhizas megallapitasara? Orv. Hetil., 2008, 149, 1943-1948.
18. Rosenbaum, M., Nicolson, M., Hirsch, J. és mtsai: Effects of gender, body composition, and menopause on plasma concentration of leptin. J. Clin. Endocrinol. Metab., 1996, 81, 3424-3427.
19. Considine, R. V., Sinha, M. K., Heiman, M. L. és mtsai: Serum immunreactive leptin concentration in normal-weight and obese humans. N. Engl. J. Med., 1996, 334, 292-295.
20. Zou, C., Shao, J.: Role of adipocytokines in obesity-associated insulin resistance. J. Nutr. Biochem., 2008, 19, 277-286.
21. Ren, J.: Leptin and hyperleptinemia - from friend to foe for cardiovascular function. J. Endocrinol., 2004, 181, 1-10.
22. Meier, U., Gressner, A. M.: Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponektin, and resistin. Clin. Chem., 2004, 50, 1511-1525.
23. Kershaw, E. E., Flier, J. S.: Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab., 2004, 89, 2548-2556.
24. Patel, S. B., Reams, G. P., Spear, R. M. és mtsai: Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr. Hypertension Rep., 2008, 10, 131-137.
25. Maiorana, A., Del Bianco, C., Cianfarani, S.: Adipose tissue: A metabolic regulator. Potential implications for the metabolic outcome of subjects born small for gestational age (SGA). Rev. Diabet. Stud., 2007, 4, 134-146.
26. Catalán, V., Gómez-Ambrosi, J., Rodríguez, A. és mtsai: Adipokines in the treatment of diabetes mellitus and obesity. Expert. Opin. Pharmacother., 2009, 10, 239-254.
27. de Ferranti, S., Mozafarrian, D.: The perfect storm: Obesity, adipocyte disfunction, and metabolic consequences. Clin. Chem., 2008, 54, 945-955.
28. Unger, R. H.: Lipotoxic diseases. Annu. Rev. Med., 2002, 53, 319-336.
29. Janeèková, R.: The role of leptin in human physiology and pathophysiology. Physiol. Res., 2001, 50, 443-459.
30. Kadowaki, T., Yamauchi, T.: Adiponectin and adiponectin receptors. Endocr. Rev., 2005, 26, 439-451.
31. Wiêcek. A., Adamczak, M., Chudek, J.: Adiponectin - an adipokine with unique metabolic properties. Nephrol. Dial. Transplant., 2007, 22, 981-988.
32. Phillips, L. K., Prins, J. B.: The link between abdominal obesity and the metabolic syndrome. Curr. Hypertens. Rep., 2008, 10, 156-164.
33. Blüher, M., Williams, C. J., Klöting, N. és mtsai: Gene expression of adiponectin receptors in human visceral and subcutaneus adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diab. Care, 2007, 30, 3110-3115.
34. Chandran, M., Phillips, S. A., Ciaraldi, T. és mtsa: Adiponectin: More than just another fat cell hormone? Diab. Care, 2003, 26, 2442-2450.
35. Fehér J., Lengyel G.: Roziglitazon es glimepirid kombinacios keszitmeny klinikai alkalmazasa 2-es tipusu diabetes mellitus kezeleseben. Orv. Hetil., 2007, 148, 2331-2335.
36. Steppan, C. M., Brown, E. J., Wright, C. M. és mtsai: A family of tissue-specifi c resistin-like molecules. Proc. Natl. Acad. Sci. USA, 2001, 98, 502-506.
37. Gómez-Ambrosi, J., Frühbeck, G.: Evidence for the involvement of resistin in infl ammation and cardiovascular disease. Curr. Diab. Rev., 2005, 1, 227-234.
38. Gerber, M., Boettner, A., Seidel, B. és mtsai: Serum resistin levels of obese and lean children and adolescents: Biochemical analysis and clinical relevance. J. Clin. Endocrinol. Metab., 2005, 90, 4503-4509.
39. Antal M., Regöly-Mérei A., Biró L. és mtsai: Az oligofruktoz hatasanak vizsgalata elhizottakban. Orv. Hetil., 2008, 149, 1989-1995.
40. Rabe, K., Lehrke, M., Parhofer, K. G. és mtsa: Adipokines and insulin resistance. Mol. Med., 2008, 14, 741-751.
41. Lee, W-J., Wu, C-S., Lin, H. és mtsai: Visfatin-induced expression of infl ammatory mediators in human endothelial cells through the NF-êB pathway Visfatin-induced expression of infl ammatory mediators. Int. J. Obes., 2009, 33, 465-472.
42. Luk, T., Malam, Z., Marshall, J. C.: Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J. Leukoc. Biol., 2008, 83, 804-816.
43. Sun, G., Bishop, J., Khalili, S. és mtsai: Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am. J. Clin. Nutr., 2007, 85, 399-404.
44. Zhu, J., Schott, M., Liu, R. és mtsai: Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes. Horm. Metab. Res., 2008, 40, 801-805.
45. Haider, D. G., Holzer, G., Schaller, G. és mtsai: The adipokine visfatin is markedly elevated in obese children. J. Ped. Gastroenterol. Nutr., 2006, 43, 548-549.
46. Chang, Y-C., Chang, T-J., Lee, W-J. és mtsa: The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with infl ammation, insulin resistance, and plasma lipids. Metabolism - Clin. Exp., 2010, 59, 93-99.
47. BioVendor: Omentin. BioVendor R&D News:1. 7. 2008, http:// news.biovendor.com/article/omentin
48. De Souza Batista, C. M., Yang, R. Z., Lee, M. J. és mtsai: Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 2007, 56, 1655-1881.
49. Pan, H-Y., Guo, L., Li, Q.: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diab. Res. Clin., 2010, 88, 29-33.